GeneDx Declares Leadership Transition

GeneDx

GeneDx officially announced a major leadership transition today. The company leads the market in rare disease diagnosis and uses genomic data to improve patient health. Everett Cunningham has been named Chief Executive Officer and member of the Board of Directors, effective on or before December 15, 2026.

With the appointment, Mr. Cunningham replaces Katherine Stueland who has previously announced her intention to resign as CEO and Board Member at this point. Ms. Stueland will remain with GeneDx as a consultant until January 31, 2027 to ensure a seamless transition.

Veteran Healthcare Executive Joins GeneDx From Quanterix

Furthermore, Mr. Cunningham brings immense industry experience to GeneDx from Quanterix Corporation. There, he most recently served as President and Chief Executive Officer. Over the past 35 years, he has built and led top commercial teams across diagnostics and genomics. His impressive background also spans medical technology and pharmaceuticals. For instance, he held senior roles at Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics, and Pfizer. Meanwhile, Mark Gardner will continue serving as President and will report directly to Mr. Cunningham.

“Everett is one of the most accomplished commercial leaders in our industry, and he is the right person to lead GeneDx into its next phase of growth,” said Keith Meister, Chairman of the GeneDx Board of Directors. “For more than three decades, Everett has built and led high-performing commercial organizations at some of the most important companies in healthcare and is uniquely positioned to move innovative diagnostics from early adoption to standard of care as we embrace the opportunity to bring exome and genome sequencing to more clinicians and families.”

Mr. Meister continued, “On behalf of the Board, I want to thank Katherine for her transformational leadership over the past five years. She led GeneDx through its combination with Sema4, delivered significant revenue growth, and helped establish GeneDx as the leader in rare disease diagnosis. We are grateful for everything she has accomplished and the lasting impact of her leadership.”

Subsequently, Mr. Cunningham shared his enthusiasm about joining the company at this pivotal moment.

“GeneDx has built a remarkable foundation, with unmatched clinical expertise, the world’s largest rare disease genomic dataset and a team that is deeply committed to the families it serves,” said Mr. Cunningham. “I have spent my career helping bring innovative diagnostics to clinicians and patients at scale, and I believe GeneDx has a tremendous opportunity to make exome and genome sequencing the first-line standard of care. I’m excited to work with GeneDx President Mark Gardner, the leadership team and the Board to accelerate adoption, execute with discipline and deliver for patients and shareholders alike.”

Similarly, Ms. Stueland reflected on her tenure and expressed confidence in the future of GeneDx.

“Five and a half years ago, I joined GeneDx as CEO to lead its transformation into an independent company, grow the business, and achieve profitability. Together, we’ve delivered on all these commitments. Most of all, I’m proud of what all this work adds up to: more families getting an accurate diagnosis sooner. Part of this journey has been building an exceptional team to lead our next phase of growth, and now is a natural time for me to pass the baton. I’m delighted to welcome Everett and look forward to seeing GeneDx go from strength to strength,” said Ms. Stueland.

Finally, GeneDx reaffirmed its full-year 2026 financial guidance. The company originally provided this outlook on November 9, 2026, alongside its third-quarter 2026 financial results.

For more stories on executive leadership and business innovations, explore our CXO Insiders for the latest updates.

Source: Businesswire

Share with friends

Latest News